Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Nov 15;61 Suppl 5(Suppl 5):S514-20.
doi: 10.1093/cid/civ672.

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age

Milagritos D Tapia  1 , Helen Findlow  2 , Olubukola T Idoko  3 , Marie-Pierre Preziosi  4 , Prasad S Kulkarni  5 , Godwin C Enwere  6 , Cheryl Elie  7 , Varsha Parulekar  8 , Samba O Sow  9 , Fadima Cheick Haidara  9 , Fatoumata Diallo  9 , Moussa Doumbia  9 , Adebayo K Akinsola  3 , Richard A Adegbola  10 , Beate Kampmann  3 , Julie Chaumont  6 , Lionel Martellet  6 , Elisa Marchetti  6 , Simonetta Viviani  6 , Yuxiao Tang  11 , Brian D Plikaytis  7 , F Marc LaForce  5 , George Carlone  7 , Ray Borrow  2
Affiliations
Clinical Trial

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age

Milagritos D Tapia et al. Clin Infect Dis. .

Abstract

Background: Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in healthy African toddlers was investigated.

Methods: African children vaccinated at 12-23 months of age with PsA-TT were followed for evaluation of antibody persistence up to 5 years after primary vaccination. Antibody persistence was evaluated by measuring group A serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific IgG enzyme-linked immunosorbent assay (ELISA).

Results: Group A antibodies measured by SBA and ELISA were shown to decline in the year following vaccination and plateaued at levels significantly above baseline for up to 5 years following primary vaccination.

Conclusions: A single dose of PsA-TT induces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccination.

Clinical trials registration: ISRTCN78147026.

Keywords: African meningitis belt; MenAfriVac; antibody persistence; group A meningococcal conjugate vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subject disposition. Abbreviations: Hib-TT, Haemophilus influenzae type b–tetanus toxoid vaccine; PsACWY, polysaccharide ACWY vaccine; PsA-TT, meningococcal A polysaccharide–tetanus toxoid protein conjugate vaccine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27(suppl 2):B13–9. - PubMed
    1. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003; 361:1902–4. - PubMed
    1. LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine 2007; 25(suppl 1):A97–100. - PubMed
    1. Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac. Hum Vaccin Immunother 2012; 8:715–24. - PubMed
    1. Djingarey MH, Barry R, Bonkoungou M et al. . Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012; 30(suppl 2):B40–5. - PubMed

Publication types

Associated data